Incidence and determinants of spontaneous cardioversion of early onset symptomatic atrial fibrillation

MV Mariani, N Pierucci, A Piro, S Trivigno, C Chimenti… - Medicina, 2022 - mdpi.com
Atrial fibrillation (AF) is the most frequent chronic arrhythmia worldwide, and it is associated
with significant morbidity and mortality, making it a considerable burden both to patients and …

A proposed strategy for anticoagulation therapy in noncompaction cardiomyopathy

C Chimenti, C Lavalle, M Magnocavallo… - ESC Heart …, 2022 - Wiley Online Library
Noncompaction cardiomyopathy (NCCM) is a rare condition characterized by prominent
trabeculae, deep intertrabecular recesses, and a left ventricular myocardium with a two …

Associations of apixaban dose with safety and effectiveness outcomes in patients with atrial fibrillation and severe chronic kidney disease

Y Xu, AR Chang, LA Inker, M McAdams-DeMarco… - Circulation, 2023 - Am Heart Assoc
BACKGROUND: Recommendations for apixaban dosing on the basis of kidney function are
inconsistent between the US Food and Drug Administration and European Medicines …

Myocardial tissue characterization in heart failure with preserved ejection fraction: from histopathology and cardiac magnetic resonance findings to therapeutic targets

P Severino, A D'Amato, S Prosperi, F Fanisio… - International Journal of …, 2021 - mdpi.com
Heart failure with preserved ejection fraction (HFpEF) is a complex clinical syndrome
responsible for high mortality and morbidity rates. It has an ever growing social and …

Managing older people with atrial fibrillation and preventing stroke: a review of anticoagulation approaches

LA Verma, PE Penson, A Akpan, GYH Lip… - Expert Review of …, 2023 - Taylor & Francis
ABSTRACT Introduction Oral anticoagulants (OACs) are the cornerstone of stroke
prevention in atrial fibrillation (AF), but prescribing decisions in older people are …

Personalizing direct oral anticoagulant therapy for a diverse population: role of race, kidney function, drug interactions, and pharmacogenetics

LE Thompson, BH Davis, R Narayan… - Clinical …, 2023 - Wiley Online Library
Oral anticoagulants (OACs) are commonly used to reduce the risk of venous
thromboembolism and the risk of stroke in patients with atrial fibrillation. Endorsed by the …

Concomitant use of diltiazem with direct oral anticoagulants and bleeding risk in atrial fibrillation

Y Xu, AR Chang, LA Inker… - Journal of the …, 2022 - Am Heart Assoc
Background Diltiazem, a moderate cytochrome P450 3A4 isozyme/P‐glycoprotein inhibitor,
may potentiate the bleeding risk of direct oral anticoagulants (DOACs) through …

Atrial fibrillation and anticoagulant treatment in end-stage renal disease patients: where do we stand?

L Di Lullo, MV Mariani, C Ronco, A Bellasi… - Cardiorenal …, 2022 - karger.com
The frequent coexistence in daily clinical practice of chronic kidney disease (CKD) and atrial
fibrillation (AF), especially in the elderly, represents a conundrum for physicians, mainly …

Prognostic value of chronic kidney disease in patients undergoing left atrial appendage occlusion

DG Della Rocca, M Magnocavallo, CJ Van Niekerk… - Europace, 2023 - academic.oup.com
Aims Atrial fibrillation (AF) and chronic kidney disease (CKD) often coexist and share an
increased risk of thrombo-embolism (TE). CKD concomitantly predisposes towards a pro …

Lower rate of major bleeding in very high risk patients undergoing left atrial appendage occlusion: A propensity score–matched comparison with direct oral …

M Magnocavallo, DG Della Rocca, G Vetta, S Mohanty… - Heart Rhythm, 2024 - Elsevier
Background Long-term oral anticoagulation is the mainstay therapy for thromboembolic (TE)
prevention in patients with atrial fibrillation. However, left atrial appendage occlusion (LAAO) …